Patents by Inventor Robert F. Kelley

Robert F. Kelley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for targeting polyubiquitin
    Patent number: 9081015
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: July 14, 2015
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20150166661
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 18, 2015
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU, Liping L. SUN
  • Anti-polyubiquitin antibodies and methods of use
    Patent number: 8992919
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: March 31, 2015
    Assignee: Genentech, Inc.
    Inventors: Vishva Dixit, Robert F. Kelley, Marissa L. Matsumoto
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20150023871
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 22, 2015
    Applicant: GENENTECH, INC.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8877897
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: November 4, 2014
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • Humanized Anti-Factor D Antibodies And Uses Thereof
    Publication number: 20140303355
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: May 20, 2014
    Publication date: October 9, 2014
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20140179905
    Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: November 14, 2013
    Publication date: June 26, 2014
    Applicant: GENENTECH, INC.
    Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
  • Methods of detecting factor D with anti-factor D antibodies
    Patent number: 8753826
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: June 17, 2014
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Methods and compositions for targeting polyubiquitin
    Patent number: 8603475
    Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: December 10, 2013
    Assignee: Genentech, Inc.
    Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
  • APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
    Publication number: 20130165383
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: April 6, 2012
    Publication date: June 27, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Sarah Hymowitz
  • APO-2 LIGAND VARIANTS AND USES THEREOF
    Publication number: 20130108578
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: May 2, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Stephanie Ho Lindstrom
  • ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE
    Publication number: 20130058955
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: August 6, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto
  • Humanized anti-factor D antibodies and uses thereof
    Patent number: 8372403
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: February 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20120230985
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 13, 2012
    Applicant: GENENTECH, INC.
    Inventors: LING-LING AN, SEK CHUNG FUNG, ROBERT F. KELLEY, HENRY B. LOWMAN, SANJAYA SINGH, HERREN WU
  • Apo-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
    Publication number: 20120165267
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: June 6, 2011
    Publication date: June 28, 2012
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Sarah Hymowitz, Stephanie Ho Lindstrom
  • Nucleic acids encoding anti-factor D antibodies
    Patent number: 8193329
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: June 5, 2012
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20120135008
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 31, 2012
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • Methods of treating with anti-factor D antibodies
    Patent number: 8187604
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: May 29, 2012
    Assignee: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Methods for making Apo-2 Ligand using divalent metal ions
    Publication number: 20120077740
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Application
    Filed: December 10, 2010
    Publication date: March 29, 2012
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • Methods and compositions for targeting polyubiquitin
    Patent number: 8133488
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: March 13, 2012
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto